Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Jan Poolman, PhD

VP Bacterial Vaccines
Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Netherlands

Disclosure(s): Janssen: Janssen Vaccines & Prevention B.V., Stocks/Bonds

Poster(s):

120 - Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
235 - Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
1823 - Clinical Profile and Antimicrobial Susceptibility of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Hospitalized Adults Aged ≥60 Years
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET